Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1965 1
1968 1
1970 1
1971 2
1972 6
1973 18
1974 15
1975 30
1976 35
1977 29
1978 16
1979 18
1980 20
1981 24
1982 14
1983 22
1984 15
1985 11
1986 15
1987 17
1988 13
1989 9
1990 19
1991 22
1992 5
1993 14
1994 6
1995 12
1996 6
1997 6
1998 13
1999 7
2000 18
2001 8
2002 14
2003 32
2004 40
2005 44
2006 51
2007 71
2008 52
2009 64
2010 92
2011 113
2012 145
2013 135
2014 145
2015 185
2016 225
2017 282
2018 397
2019 587
2020 869
2021 1004
2022 1090
2023 1076
2024 673

Text availability

Article attribute

Article type

Publication date

Search Results

6,908 results

Results by year

Filters applied: . Clear all
Page 3
Cannabidiol and periodontal inflammatory disease: A critical assessment.
Jirasek P, Jusku A, Simanek V, Frankova J, Storch J, Vacek J. Jirasek P, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):155-160. doi: 10.5507/bp.2022.012. Epub 2022 Mar 21. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022. PMID: 35332345 Free article. Review.
Cannabidiol (CBD), a non-psychotropic cannabinoid produced by the genus Cannabis, is a phytoceutical that activates the endocannabinoid system (ECS) through binding to CB1 and CB2 receptors. ...
Cannabidiol (CBD), a non-psychotropic cannabinoid produced by the genus Cannabis, is a phytoceutical that activates the endocannabino
Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).
Good P, Haywood A, Gogna G, Martin J, Yates P, Greer R, Hardy J. Good P, et al. BMC Palliat Care. 2019 Dec 6;18(1):110. doi: 10.1186/s12904-019-0494-6. BMC Palliat Care. 2019. PMID: 31810437 Free PMC article. Clinical Trial.
There is increasing interest in the use of medicinal cannabinoids, but there is little high quality evidence to guide clinicians. This study aims to define the role of cannabidiol (CBD) in the management of symptom burden in patients with advanced cancer undergoing standar …
There is increasing interest in the use of medicinal cannabinoids, but there is little high quality evidence to guide clinicians. This study …
Cannabidiol inhibits Na(v) channels through two distinct binding sites.
Huang J, Fan X, Jin X, Jo S, Zhang HB, Fujita A, Bean BP, Yan N. Huang J, et al. Nat Commun. 2023 Jun 17;14(1):3613. doi: 10.1038/s41467-023-39307-6. Nat Commun. 2023. PMID: 37330538 Free PMC article.
Cannabidiol (CBD), a major non-psychoactive phytocannabinoid in cannabis, is an effective treatment for some forms of epilepsy and pain. ...
Cannabidiol (CBD), a major non-psychoactive phytocannabinoid in cannabis, is an effective treatment for some forms of epilepsy and pa
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies.
Schoevers J, Leweke JE, Leweke FM. Schoevers J, et al. Curr Opin Psychiatry. 2020 May;33(3):185-191. doi: 10.1097/YCO.0000000000000596. Curr Opin Psychiatry. 2020. PMID: 32073423 Review.
Regarding side effects and tolerability, cannabidiol induced sedation in one study, with the other studies indicating good tolerability, even at high doses. SUMMARY: Recent clinical trials added further evidence for an antipsychotic potential of cannabidiol. In gene …
Regarding side effects and tolerability, cannabidiol induced sedation in one study, with the other studies indicating good tolerabili …
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D. Samanta D. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Pediatr Neurol. 2019. PMID: 31053391 Review.
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have a novel anticonvulsant effect. ...Additionally, the FDA-approved pharmaceutical-grade cannabidiol oil is expensive, and insurance co …
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have …
Cannabidiol As a Treatment for COVID-19 Symptoms? A Critical Review.
Holst M, Nowak D, Hoch E. Holst M, et al. Cannabis Cannabinoid Res. 2023 Jun;8(3):487-494. doi: 10.1089/can.2021.0135. Epub 2022 Jul 26. Cannabis Cannabinoid Res. 2023. PMID: 35881839 Review.
Internationally, a debate emerged about potential benefits of cannabidiol (CBD) as treatment of corona virus disease-19 (COVID-19). ...
Internationally, a debate emerged about potential benefits of cannabidiol (CBD) as treatment of corona virus disease-19 (COVID-19). . …
Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?
Lord S, Hardy J, Good P. Lord S, et al. Curr Treat Options Oncol. 2022 Apr;23(4):514-525. doi: 10.1007/s11864-021-00934-0. Epub 2022 Mar 22. Curr Treat Options Oncol. 2022. PMID: 35316478 Free PMC article. Review.
Patients with advanced cancer experience many distressing symptoms, with some turning to medicinal cannabis to help alleviate these. Focus has fallen on cannabidiol (CBD) as a potential treatment for a variety of symptoms in advanced cancer due to the lack of psychoactive …
Patients with advanced cancer experience many distressing symptoms, with some turning to medicinal cannabis to help alleviate these. Focus h …
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. McGuire P, et al. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. Am J Psychiatry. 2018. PMID: 29241357 Clinical Trial.
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. ...
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed th …
Cannabidiol and Sodium Channel Pharmacology: General Overview, Mechanism, and Clinical Implications.
Ghovanloo MR, Ruben PC. Ghovanloo MR, et al. Neuroscientist. 2022 Aug;28(4):318-334. doi: 10.1177/10738584211017009. Epub 2021 May 24. Neuroscientist. 2022. PMID: 34027742 Free PMC article. Review.
The main non-psychotropic constituent of the cannabis plant, cannabidiol (CBD), has recently gained interest as a viable compound to treat some of the conditions that are associated with Nav malfunctions. ...
The main non-psychotropic constituent of the cannabis plant, cannabidiol (CBD), has recently gained interest as a viable compound to …
Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM, Mali S, Amin PD, Oliveira M. Tambe SM, et al. J Integr Med. 2023 May;21(3):236-244. doi: 10.1016/j.joim.2023.03.004. Epub 2023 Mar 18. J Integr Med. 2023. PMID: 36973157 Review.
Cannabidiol (CBD), a nonpsychotropic phytocannabinoid that was once largely disregarded, is currently the subject of significant medicinal study. ...Please cite this article as: Tambe SM, Mali S, Amin PD, Oliveira M. Neuroprotective potential of Cannabidiol: Molecul
Cannabidiol (CBD), a nonpsychotropic phytocannabinoid that was once largely disregarded, is currently the subject of significant medi
6,908 results